This medicine is composed of the active ingredient Repaglinide. This active ingredient belongs to the group of drugs known as meglitinide. It has a hypoglycemic activity. This active medication is rapidly absorbed and has a rapid onset and short duration of action. It is an antihyperglycemic agent indicated for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is insulin secretagogues that act by binding to cells of the pancreas to stimulate insulin release. It also induces an early insulin response to meals reducing postprandial blood glucose levels.
This mentioned medication is indicated alone or with other drugs to control high blood sugar. It must be taken along with a proper diet and exercise program. Prandin is approved in people with type 2 diabetes. Lowering high blood sugar prevents kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Controlling diabetes may also lessen the risk of a heart attack or stroke. This drug stimulates the body to make more insulin, which is a natural substance that allows the body to use sugar properly absorbed from the diet.
Repaglinide composed of medicine might be more potent in persons with more moderate abnormalities of blood glucose levels. It has a rapid onset of action and a short duration of action. Prandin promotes the release of insulin that normally occurs with meals and prevents blood glucose levels from becoming high. It also lowers hemoglobin A1c levels by 1.6% to 1.9%.
This medication is available in dosages as mentioned below:
- 0.5 mg: It is to be consumed orally 2 to 4 times a day within 30 minutes before each meal as directed by the doctor
- 1 mg: Consume this medicine a2 to 4 times a day before a meal as advised by the doctor
- 2 mg: This drug shall be taken before each meal as prescribed by the doctor
This drug shall not be consumed by people who have type 1 diabetes, severe liver disease, or diabetic ketoacidosis.